Sullivan P. Prevention by the pound. CMAJ. 2010 Aug 30. [Epub ahead of print] Hanley GE, Morgan S, Barer M, Reid RJ. The redistributive effect of the move from age-based to income-based prescription drug coverage in British Columbia, Canada. Health Policy. 2011 Jan 19.
Guertin JR, Jackevicius CA, Cox JL et al. The potential economic impact of restricted access to angiotensin-receptor blockers. CMAJ. 2011 Jan 24th.
Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of national findings. Rockville MD: U.S. Substance Abuse and Mental Health Services Administration, 2010.
Effects of using generic drugs on Medicare’s prescription drug spending: A CBO study. Washington DC: Congress of the United States. Congressional Budget Office; September 2010.
Kelley RK, Venook AP. Nonadherence to imatinib during an economic downturn. N Engl J Med. 2010 Aug 5;363(6):596-8.
Wagner AK, Graves AJ, Reiss SK et al. Access to care and medicines, burden of health care expenditures, and risk protection: Results from the World Health Survey. Health Policy. 2010 Sep 7.
Baldini CG, Culley EJ. Estimated cost savings associated with the transfer of office-administered specialty pharmaceuticals to a specialty pharmacy provider in a medical injectable drug program. J Manag Care Pharm. 2011-Feb;17(1):51-9.
The use of medicines in the United States: Review of 2010. Parsippany NJ: IMS Institute for Healthcare Informatics; 2011.Subbaraman N. Flawed arithmetic on drug development costs. Nat Biotechnol. 2011 May;29(5):381.
Doloresco F, Fominaya C, Schumock GT et al. Protecting future drug expenditures - 2011. Am J Health Syst Pharm. 2011 May 15;68(10): 921-32.
Treatment Episode Data Set (TEDS). 1999 - 2009: National Admissions to Substance Abuse Treatment Services. DASIS Series: S-56, HHS Publication No. (SMA) 11-4646. Rockville MD: US Substance Abuse and Mental Health Services Administration; 2011.
An international survey on pharmacists’ views on their changing roles. Supported by a grant from Pfizer in collaboration with FIP. The Hague NE: International Pharmaceutical Federation (FIP); August 2010, Powerpoint® presentation.
Van Puymbroeck RV. Basic survival needs and access to medicines - coming to grips with TRIPS: Conversion + calculation. J Law Med Ethics. 2010 Sep;38(3):520-49.
Pope TM. Legal briefing: Conscience clauses and conscientious refusal. J Clin
Ethics. 2010 Summer;21(2):163-76.
Friedman AJ, Cosby R, Boyko S et al. Effective Teaching Strategies and Methods of Delivery of Patient Education: A Systematic Review and Practice Guideline Recommendations. J Cancer Educ. 2010 Dec 16.
Lucado J, Paez K, Elixhauser A. Medication-Related Adverse Outcomes in U.S.
Hospitals and Emergency Departments, 2008: Statistical Brief #109. 2011 Apr.
Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet].
Rockville (MD): Agency for Health Care Policy and Research (US); 2006 Feb-.
Pharmacist Work Force
Pharmacy as a Career
Skinner BJ, Rovere M. Canada's Medicare Bubble: Is government health spending sustainable without user-based funding? Studies in healthcare policy. Vancouver BC: Fraser Institute; April 2011.
Shrank WH, Liberman JN, Fischer MA, Girdish C, Brennan TA, Choudhry NK. Physician perceptions about generic drugs (January). Ann Pharmacother. 2011 Jan 4. [Epub ahead of print]
Health, United States, 2010: With special feature on death and dying. Hyattsville MD: US National Center for Health Statistics; 2011.
Occupational Employment Statistics. Occupational employment and wages, May 2009: 29-1051 pharmacists. Washington DC: U.S. Bureau of Labor Statistics; last modified May 14, 2010.
Featherstone H, Whitham L. The cost of cancer. London: Policy Exchange; February 2010.
Roebuck MC, Liberman JN, Gemill-Toyama M, Brennan TA. Medication Adherence Leads to Lower Healthcare Use and Costs Despite Increased Drug Spending. Health Aff (Millwood). 2011 Jan ;30(1): 91-9.